PP405
also JXL069, Suvomipic
Suvomipic is a drug acting as a mitochondrial pyruvate carrier (MPC) inhibitor which is under development for the treatment of alopecia, specifically androgenic alopecia. It is used topically as a 0.05% concentration gel on the scalp once-daily. Suvomipic is a possible first-in-class drug with a novel mechanism of action in the potential treatment of hair loss. The drug's generic name and chemical structure were published in July 2026, revealing PP405 to be the existing compound JXL069.
Read “Suvomipic” on Wikipedia · text from Wikipedia, CC BY-SA 4.0
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research 4
- PP405 in Alopecia: An Emerging Molecule worth Investigating
- Diagnostic Comparison: SH‑1 Molecule vs PP405 — Safety Profiles in Hair Science
- LB1045 Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo
- Review of the 2024 American Academy of Dermatology (AAD) Annual Meeting
Community 10
- Phase 3 Study for PP405 officially posted
- The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?
- Pelage Pharmaceuticals Phase 3 Trials for PP405 Start in September 2026
- Sprinkle that PP405 on my scalp like I sprinkle salt on my stake
- Pelage have made a new post about PP405
- I wrote a poem about pp405 (potential treatment)
- Pelage will be presenting PP405 at the Masters of Aesthetics which is held from 28-30th August
- PP405 Drug in Action: Picture From Official Company Website
- Phase 3 for PP405 will now start in 2027
- Why is everyone still arguing about PP405 when clascoterone is already heading toward regulatory submission?